The quarter beat a reasonable market bar, but not by enough to reset the outlook. Published expectations were roughly $3.88 for diluted EPS and $3.50 billion of revenue; DaVita delivered $4.02 and $3.554 billion, respectively.
| Metric | Q2 2026 | Comparison / expectation |
|---|---|---|
| Revenue | $3.554B (Income Statement) | ~$3.50B consensus |
| Diluted EPS | $4.02 (Income Statement) | ~$3.88 consensus |
| Operating income | $579M; 16.3% margin (Financial Highlights) | $482M; 14.1% in Q1 |
| Adjusted operating income | $579M (Non-GAAP reconciliation) | $482M in Q1; no current adjustment needed |
| Operating cash flow | $490M (Cash Flow) | $321M in Q1; $324M in Q2 2025 |
| Free cash flow | $256M (Free Cash Flow reconciliation) | $140M in Q1; $157M in Q2 2025 |
| 2026 adjusted operating income guidance | $2.15B-$2.25B (Current 2026 guidance) | Reaffirmed |
| 2026 adjusted EPS guidance | $14.10-$15.20 (Current 2026 guidance) | Reaffirmed |
| 2026 free cash flow guidance | $1.00B-$1.25B (Current 2026 guidance) | Reaffirmed |
Underlying operations improved sequentially, but growth remains modest. U.S. dialysis treatments rose 1.1% from Q1 on a daily basis, while normalized non-acquired treatment growth was only 0.3% year over year (U.S. dialysis metrics). The more important margin signal was cost control: patient care cost per treatment fell $2.71 sequentially to $277.40, while revenue per treatment declined $1.72 to $415.87 because of payor mix and other normal fluctuations (U.S. dialysis metrics). That combination produced the operating-margin expansion from 14.1% to 16.3% (Financial Highlights), rather than a broad acceleration in pricing or volume.
Cash generation was a clear supporting positive. First-half operating cash flow reached $811 million versus $504 million in the prior-year period, and free cash flow reached $396 million versus $290 million implied by the quarterly reconciliation for the first half of 2025 (Cash Flow statement; Free Cash Flow reconciliation). Last-twelve-month free cash flow increased to $1.308 billion from $947 million, giving the reaffirmed $1.00-$1.25 billion full-year target useful cushion (Cash Flow summary). DaVita also repurchased $751 million of stock in the first half, although debt increased to $10.848 billion after the new $500 million Term Loan B-2 tranche (Debt and capital structure; Debt transaction).
The net read is a modest earnings beat, not a guidance inflection. EPS and revenue came in above consensus, and cash flow and margins improved, but treatment growth is still low and revenue per treatment moved backward sequentially. Management left all 2026 targets unchanged rather than raising them (Current 2026 guidance), so the filing improves confidence in execution against the existing plan without materially lifting the market's forward assumptions.
Read the original 8-K on SEC EDGAR ↗